FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2021-08, Vol.27 (16), p.4478-4485
Hauptverfasser:	Narayan, Preeti, Osgood, Christy L, Singh, Harpreet, Chiu, Haw-Jyh, Ricks, Tiffany K, Chiu Yuen Chow, Edwin, Qiu, Junshan, Song, Pengfei, Yu, Jingyu, Namuswe, Frances, Guiterrez-Lugo, Maria, Hou, Sherry, Pierce, William F, Goldberg, Kirsten B, Tang, Shenghui, Amiri-Kordestani, Laleh, Theoret, Marc R, Pazdur, Richard, Beaver, Julia A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Camptothecin - analogs & derivatives Camptothecin - therapeutic use Drug Approval Female Humans Immunoconjugates - therapeutic use Middle Aged Receptor, ErbB-2 - analysis Trastuzumab - therapeutic use United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!